GeoVax Labs’ (GOVX) “Hold” Rating Reiterated at D. Boral Capital

D. Boral Capital reiterated their hold rating on shares of GeoVax Labs (NASDAQ:GOVX) in a report issued on Thursday, Marketbeat Ratings reports.

Several other research firms have also recently weighed in on GOVX. Wall Street Zen cut GeoVax Labs to a “strong sell” rating in a report on Saturday, January 17th. Weiss Ratings reissued a “sell (e+)” rating on shares of GeoVax Labs in a research note on Thursday, January 22nd. One research analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock has an average rating of “Reduce” and a consensus target price of $150.00.

GeoVax Labs Trading Up 0.8%

Shares of GeoVax Labs stock opened at $1.24 on Thursday. The company has a market capitalization of $2.26 million, a PE ratio of -0.04 and a beta of 3.81. GeoVax Labs has a 12 month low of $1.14 and a 12 month high of $34.75. The stock’s fifty day simple moving average is $1.59 and its 200 day simple moving average is $6.33.

GeoVax Labs (NASDAQ:GOVX) last posted its earnings results on Wednesday, April 15th. The company reported $1.85 earnings per share (EPS) for the quarter. Analysts predict that GeoVax Labs will post -4.49 EPS for the current fiscal year.

Institutional Trading of GeoVax Labs

Hedge funds and other institutional investors have recently modified their holdings of the company. Jane Street Group LLC bought a new stake in shares of GeoVax Labs in the fourth quarter valued at about $99,000. HRT Financial LP bought a new position in shares of GeoVax Labs during the fourth quarter worth about $31,000. Renaissance Technologies LLC acquired a new stake in GeoVax Labs in the 4th quarter valued at approximately $104,000. Hudson Bay Capital Management LP acquired a new stake in GeoVax Labs in the 3rd quarter valued at approximately $47,000. Finally, Armistice Capital LLC bought a new stake in GeoVax Labs in the 3rd quarter valued at approximately $253,000. Institutional investors and hedge funds own 6.09% of the company’s stock.

GeoVax Labs Company Profile

GeoVax Labs, Inc is a clinical-stage biotechnology company focused on the development of novel vaccines and immunotherapies against infectious diseases. Leveraging a proprietary Modified Vaccinia Ankara (MVA) viral vector platform, GeoVax aims to induce robust and durable immune responses by expressing virus-like particles (VLPs) in vaccinated individuals. The company’s pipeline encompasses vaccine candidates for HIV, Ebola, Lassa, Zika, MERS and emerging coronaviruses, reflecting a commitment to addressing high-priority global public health threats.

The cornerstone of GeoVax’s technology is its MVA-VLP platform, which combines the safety profile of a non-replicating poxvirus vector with the potent antigen presentation of VLPs.